Immune Biomarkers May Predict Response to Bladder Cancer Treatment
A Northwestern Medicine study has offered new clues as to why immunotherapy works well for some bladder cancer patients but fails for others, according to a study published in the Journal of Clinical…
Read the full articleYou might also wanna read
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in p
Gut microbiome composition predicts melanoma recurrence risk in patients on immunotherapy, large trial finds
In 674 high-risk melanoma patients across five regions, the gut microbiome differs by region but remains stable during ICB treatment, and re
10x Genomics, Cleveland Clinic Collaborate on Single-Cell, Spatial Diagnostics
The partners hope to better understand the mechanisms underlying therapeutic response in a number of major cancer types, including bladder c
Mayo Clinic study reveals immune cells begin preparing to fight cancer earlier than thought
ROCHESTER, Minn. — Researchers at Mayo Clinic have uncovered a previously hidden step in how the immune system prepares to fight cancer, a d
mayocl.in·15d agoFDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with
Nectin4-targeted fluorescence imaging probe improves bladder cancer detection and surgical precision
He et al. develop NECTIN4-ICG, a Nectin4-targeted fluorescence imaging probe for bladder cancer. In preclinical models and clinical trials,
Comments
Sign in to join the conversation.
No comments yet. Be the first.